In one such study, HIF1α expression showed no correlation with the therapeutic effects of neo-adjuvant hormone therapy post radical prostatectomy in prostate adenocarcinoma, although it was hypothesized that HIF1α might be a useful biomarker for predicting early castration resistance with hormone therapy [31]. The gene discussed is HIF1A; the disease is prostate adenocarcinoma.